User: Guest  Login
Title:

Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.

Document type:
Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Article
Author(s):
Lorenzen, Sylvie; Riera Knorrenschild, Jorge; Haag, Georg-Martin; Pohl, Michael; Thuss-Patience, Peter; Bassermann, Florian; Helbig, Ulrike; Weißinger, Florian; Schnoy, Elisabeth; Becker, Klaus; Stocker, Gertraud; Rüschoff, Josef; Eisenmenger, Andreas; Karapanagiotou-Schenkel, Irini; Lordick, Florian
Abstract:
Human epidermal growth factor receptor 2 (HER2) amplification is present in a subgroup of gastroo-esophageal cancers (GCs). HER2 inhibition with trastuzumab has shown to improve outcomes in advanced disease. Lapatinib ditosylate (LAP), a dual anti-epidermal growth factor receptor (EGFR) and anti-HER2 tyrosine kinase inhibitor with preclinical activity against GC, has been approved in HER2-positive breast cancer. We aimed to study the activity of LAP in HER2-amplified GC.Patients (pts) with HER2-...     »
Journal title abbreviation:
Eur J Cancer
Year:
2015
Journal volume:
51
Journal issue:
5
Pages contribution:
569-76
Language:
eng
Fulltext / DOI:
doi:10.1016/j.ejca.2015.01.059
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/25694417
Print-ISSN:
0959-8049
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX